Umbralisib shows early promise for patients with marginal zone lymphoma
ATLANTA -- The investigational therapeutic umbralisib, which targets the molecule PI3K-delta, was well tolerated and highly active in patients with relapsed/refractory marginal zone lymphoma, according...







